Last reviewed · How we verify
NBP608
NBP608 is a novel therapeutic agent in development by SK Chemicals, currently in phase 3 clinical trials.
At a glance
| Generic name | NBP608 |
|---|---|
| Sponsor | SK Chemicals Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding the specific mechanism of action for NBP608. As a phase 3 candidate from SK Chemicals, it represents an advanced-stage investigational drug, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases or literature.
Approved indications
Common side effects
Key clinical trials
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years (PHASE3)
- Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age (PHASE3)
- Safety Study of NBP608 in Healthy Adult Volunteers (PHASE1)
- Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over (PHASE3)
- Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over (PHASE2, PHASE3)
- The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |